Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
tamoxifen citrate, Quantity: 30.34 mg (Equivalent: tamoxifen, Qty 20 mg)
Southern Cross Pharma Pty Ltd
Tablet
Excipient Ingredients: lactose monohydrate; maize starch; magnesium stearate; brilliant scarlet 4R; povidone
Oral
60, 30
(S4) Prescription Only Medicine
Treatment of breast cancer TAMOXIFEN LUPIN is indicated for the treatment of breast cancer.,Primary reduction of breast cancer risk TAMOXIFEN LUPIN is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).
Visual Identification: Pink, round biconvex tablets; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2020-07-24
TAMOXIFEN LUPIN V 1.0 1 TAMOXIFEN LUPIN TABLETS _Tamoxifen (as citrate) _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Tamoxifen Lupin tablets. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Tamoxifen Lupin tablets against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT TAMOXIFEN LUPIN IS USED FOR Tamoxifen Lupin tablets are used to treat breast cancer or reduce the risk of breast cancer occurring if you are at increased risk of breast cancer. If you and your healthcare professional are considering using Tamoxifen Lupin for reducing the risk of breast cancer occurring, your knowledge of treatment risks becomes more important because you don't currently have breast cancer. Tamoxifen Lupin therapy may be uncommonly associated with serious side effects such as deep vein thrombosis (DVT - blood clots in veins of your leg), pulmonary embolus (blood clots in your lungs) and uterine cancer. In some women, these events were fatal. Less serious side effects such as hot flushes, vaginal discharge, menstrual irregularities and gynaecological conditions may also occur. Whether the benefits of treatment outweigh the risks depends on your age, health history, your level of breast cancer risk and on your personal judgement. Tamoxifen Lupin therapy to reduce the risk of breast cancer may not be appropriate for all women at increased risk for breast cancer. An assessment with your healthcare professional of the potential benefits and risks prior to starting therapy for reduction in breast cancer risk is essential. You should understand that Tamoxifen Lupin reduces, but does not eliminate, the risk of breast cancer. Tamoxifen Lupin contains the active ingredient ta Read the complete document
Tamoxifen Lupin v 1.0 AUSTRALIAN PRODUCT INFORMATION TAMOXIFEN LUPIN (TAMOXIFEN (AS CITRATE)) TABLETS 1 NAME OF THE MEDICINE Tamoxifen (as citrate). 2 QUALITATIVE AND QUANTITATIVE COMPOSITION TAMOXIFEN LUPIN tablets contain 20 mg tamoxifen (as citrate) Excipients with known effect: Contains sugars as lactose For the full list of excipients, see Section 6.1 List of excipients . 3 PHARMACEUTICAL FORM Tamoxifen (as citrate) 20 mg tablets are pink, round and biconvex. 4 CLINICAL PARTICULARS 4.1 T HERAPEUTIC INDICATIONS TREATMENT OF BREAST CANCER TAMOXIFEN LUPIN is indicated for the treatment of breast cancer. PRIMARY REDUCTION OF BREAST CANCER RISK TAMOXIFEN LUPIN is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average). 4.2 D OSE AND METHOD OF ADMINISTRATION ADULTS TREATMENT OF BREAST CANCER The initial dose is 20 mg once daily. In advanced breast cancer, if no response is seen, dosage may be increased to 40 mg once daily. PRIMARY REDUCTION OF BREAST CANCER RISK The recommended maximum dose is 20 mg daily for 5 years. There are insufficient data to support a higher dose or longer period of use. An assessment of the potential benefits and risks prior to starting therapy for reduction in breast cancer risk is essential. Validated algorithms are available that calculate breast cancer risk based on features such as age, family history, genetic factors, reproductive factors, and history of breast disease. TAMOXIFEN LUPIN reduces, but does not eliminate, the risk of breast cancer. In clinical trials, tamoxifen decreased the incidence of oestrogen receptor-positive tumours, but did not alter the incidence of oestrogen receptor-negative tumours. The use of tamoxifen should be as part of a program including regular breast surveillance tailored to the individual woman, taking into account the risk of breast cancer. Tamoxifen Read the complete document